If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The latter delivery combination was tested on mice and proved to be effective against leukemia, lymphoma, breast, ovarian, neuroblastoma and prostate cancers. The medium half-life of 227Ac (21.77 years) makes it a very convenient radioactive isotope in modeling the slow vertical mixing of oceanic waters. The associated processes cannot be studied with the required accuracy by direct measurements of current velocities (of the order 50 meters per year). However, evaluation of the concentration depth profiles for different isotopes allows estimating the mixing rates. The physics behind this method is as follows: oceanic waters contain homogeneously dispersed 235U. Its decay product, 231Pa, gradually precipitates to the bottom, so that its concentration first increases with depth and then stays nearly constant. 231Pa decays to 227Ac; however, the concentration of the latter isotope does not follow the 231Pa depth profile, but instead increases toward the sea bottom. This occurs because of the mixing processes, which raise some additional 227Ac from the sea bottom. Thus, analysis of both 231Pa and 227Ac depth profiles allows researchers to model the mixing behavior. There are theoretical predictions that AcHx hydrides (in this case with very high pressure) are a candidate for a near room-temperature superconductor as they have Tc significantly higher than H3S, possibly near 250 K.
RX871024 is an experimental drug containing an imidazoline moiety, developed by Reckitt Benckiser. The development of RX871024 was discontinued in 1997. It is known for its potent ability to enhance insulin action. RX871024 stimulates insulin secretion from pancreatic beta cells through multiple mechanisms.
== Classification == Surfactants are compounds with hydrophilic "heads" and hydrophobic "tails." The "heads" of surfactants are polar and may or may not carry an electrical charge. The "tails" of most surfactants are fairly similar, often consisting of a hydrocarbon chain (linear or branched) and may comprise aromatic units. Most commonly, surfactants are classified according to the polarity of their head group: A non-ionic surfactant has no charged groups in its head. The head of an ionic surfactant carries a net positive, or negative, charge. If the charge is negative, the surfactant is more specifically called anionic; if the charge is positive, it is called cationic. If a surfactant contains a head with two oppositely charged groups, it is termed zwitterionic, or amphoteric.
Sources: en.wikipedia.org
The 1980s MGN W12 F1 engine used rotary valves but never raced. Between 2002 and 2004 the Australian developer Bishop Innovation and Mercedes-Ilmor tested rotary valves for a F1 V10 engine. Bishop Innovations' patent for the rotary valve engine was bought out by BRV Pty Ltd, owned by Tony Wallis, one of the valves original designers. BRV has constructed several functional motors using the rotary valve technology, such as a Honda CRF 450, which had greater torque at both low (17% increase) and high (9% increase) engine speeds, and also produced more brake horsepower up to around 30% more at functional engine speeds. The engine was also considerably smaller and lighter, as the cylinder head assembly was not as large. A company in the UK called Roton Engine Developments made some progress in 2005 with a two-rotor (one for inlet and one for exhaust) single-cylinder Husaberg motorcycle engine. They filed patents and got an example running in 2006, but were backed by MG Rover which subsequently went bust, leaving Roton without enough funds to continue. The designs surfaced some years later in Australia with Engine Developments Australia Pty Ltd. A prototype casting was produced in 2013 on a Kawasaki Ninja 300 parallel twin unit.
MiaB introduces a methylthio group to the isopentenylated A37 derivatives in the tRNA of S. Typhimurium and E. coli by utilizing one SAM molecule to generate 5'-dAdo radical to activate the substrate and a second SAM to donate a sulfur atom to the substrate. RimO is responsible for post-translational modification of Asp88 of the ribosomal protein S12 in E. coli. The crystal structure sheds light on the mechanistic action of RimO. The enzyme catalyzes pentasulfide bridge formation linking two Fe-S clusters to allow for sulfur insertion to the substrate. eMtaB is the designated methylthiotransferase in eukaryotic and archaeal cells. eMtaB catalyzes the methylthiolation of tRNA at position 37 on N6-threonylcarbamoyladenosine. A bacterial homologue of eMtaB, YqeV has been reported and suggested to function similarly to MiaB and RimO.
Bush began his presidency with approval ratings near 60 percent. After the September 11 attacks, Bush gained an approval rating of 90 percent, maintaining 80–90 percent approval for four months after the attacks. It remained over 50 percent during most of his first term and then fell to as low as 19 percent in his second term. In 2000 and again in 2004, Time magazine named George W. Bush as its Person of the Year, a title awarded to someone who the editors believe "has done the most to influence the events of the year". In May 2004, Gallup reported that 89 percent of the Republican electorate approved of Bush. However, the support waned due mostly to a minority of Republicans' frustration with him on issues of spending, illegal immigration, and Middle Eastern affairs. Within the United States armed forces, according to an unscientific survey, the president was strongly supported in the 2004 presidential elections. While 73 percent of military personnel said they would vote for Bush, 18 percent preferred his Democratic rival, John Kerry. According to Peter Feaver, a Duke University political scientist who has studied the political leanings of the U.S. military, members of the armed services supported Bush because they found him more likely than Kerry to complete the War in Iraq. Bush's approval rating surged to 74 percent at the beginning of the Iraq War, up 19 points from his pre-war rating of 55 percent. Bush's approval rating went below the 50 percent mark in AP-Ipsos polling in December 2004.
Sources: en.wikipedia.org
=== Nonlinear curve fitting === Nonlinear curve-fitting programs, such as Equilibrium Binding Data Analysis (EBDA) and LIGAND, are used to calculate estimates of binding parameters from saturation and competition-binding experiments. EBDA performs the initial analysis, which converts measured radioactivity into molar concentrations and creates Hill slopes and Scatchard transformations from the data. The analysis made by EBDA can then be used by LIGAND to estimate a specified model for the binding.
=== Diagnostic uses === The transaminase enzymes are important in the production of various amino acids, and measuring the concentrations of various transaminases in the blood is important in the diagnosing and tracking many diseases. For example, the presence of elevated transaminases can be an indicator of liver and cardiac damage. Two important transaminase enzymes are aspartate transaminase (AST), also known as serum glutamic oxaloacetic transaminase (SGOT); and alanine transaminase (ALT), also called alanine aminotransferase (ALAT) or serum glutamate-pyruvate transaminase (SGPT). These transaminases were discovered in 1954 and their clinical importance was described in 1955.
It was like a cloudy day all day long, in fact, we didn’t realize it was smoke at first. The smoke was about 500 feet above us, so we couldn’t see the sky. However, we could see horizontally for long distances with no problem. We knew it was smoke when the mucous from our nostrils started to look black..." A paper published in 2000 analyzed the degree of exposure by troops to particulate matter, including soot. However, the paper focused more-so on silica sand, which can produce silicosis. The paper included troop medical records, and in its conclusion: "A literature review indicated negligible to nonexistent health risk from other inhaled particulate material (other than silica) during the Gulf War".
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.